ABVC BioPharma, Inc. (ABVC)Healthcare | Biotechnology | Fremont, United States | NasdaqCM
1.32 USD
+0.09
(7.317%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.25 -0.07 (-0.070%) ⇩ (April 17, 2026, 7:48 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:28 p.m. EDT
ABVC BioPharma, Inc. is currently in a weak position with negative fundamentals and a declining price trend. The recent price history shows a downward spiral, and there are no dividends to provide income. The forecasting model suggests a negative short-term outlook, and the options activity does not provide clear signals for a directional move. This stock is not suitable for short-term trading or long-term holding due to its poor fundamentals and lack of positive indicators. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.188986 |
| AutoETS | 0.369884 |
| MSTL | 0.372207 |
| AutoARIMA | 0.381097 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 12.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.393 |
| Excess Kurtosis | -0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 26.119 |
| Market Cap | 33,841,136 |
| Forward P/E | -3.00 |
| Beta | 0.38 |
| Previous Name | American BriVision (Holding) Corporation |
| Website | https://www.abvcpharma.com |
As of April 11, 2026, 4:28 p.m. EDT: The options data indicates a lack of significant activity, with minimal open interest and volume in both calls and puts. The calls show some positioning at higher strikes, suggesting potential bullish sentiment, but the puts have significant volume at higher strikes, indicating possible bearish speculation. The overall low implied volatility and limited open interest suggest uncertainty or lack of consensus among options traders regarding the stock's future direction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4089347 |
| Address1 | 44,370 Old Warm Springs Boulevard |
| All Time High | 7,165,605.0 |
| All Time Low | 0.343949 |
| Ask | 1.41 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 215,020 |
| Average Daily Volume3 Month | 84,370 |
| Average Volume | 84,370 |
| Average Volume10Days | 215,020 |
| Beta | 0.383 |
| Bid | 1.28 |
| Bid Size | 1 |
| Book Value | 0.457 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.32 |
| Current Ratio | 0.406 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.4 |
| Day Low | 1.22 |
| Debt To Equity | 26.119 |
| Display Name | ABVC BioPharma |
| Dividend Date | 1,557,273,600 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda | -7,125,929 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.267 |
| Enterprise Value | 37,529,804 |
| Eps Forward | -0.44 |
| Eps Trailing Twelve Months | -0.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.38358 |
| Fifty Day Average Change | -0.06357992 |
| Fifty Day Average Change Percent | -0.04595319 |
| Fifty Two Week Change Percent | 40.89347 |
| Fifty Two Week High | 5.48 |
| Fifty Two Week High Change | -4.16 |
| Fifty Two Week High Change Percent | -0.75912404 |
| Fifty Two Week Low | 0.806 |
| Fifty Two Week Low Change | 0.51400006 |
| Fifty Two Week Low Change Percent | 0.6377172 |
| Fifty Two Week Range | 0.806 - 5.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,100,097,000,000 |
| Float Shares | 19,881,725 |
| Forward Eps | -0.44 |
| Forward P E | -3.0000002 |
| Free Cashflow | 721,904 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18978001 |
| Held Percent Institutions | 0.03398 |
| Implied Shares Outstanding | 25,637,225 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-08-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,690,243,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. |
| Long Name | ABVC BioPharma, Inc. |
| Market | us_market |
| Market Cap | 33,841,136 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_325748154 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-16 |
| Net Income To Common | -7,908,554 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 34,097,509 |
| Open | 1.23 |
| Operating Cashflow | -2,986,299 |
| Operating Margins | 3.75824 |
| Payout Ratio | 0.0 |
| Phone | 510 668 0881 |
| Post Market Change | -0.06950009 |
| Post Market Change Percent | -5.265158 |
| Post Market Price | 1.2505 |
| Post Market Time | 1,776,469,727 |
| Prev Name | American BriVision (Holding) Corporation |
| Previous Close | 1.23 |
| Price Hint | 4 |
| Price To Book | 2.888403 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.121 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.09 |
| Regular Market Change Percent | 7.31708 |
| Regular Market Day High | 1.4 |
| Regular Market Day Low | 1.22 |
| Regular Market Day Range | 1.22 - 1.4 |
| Regular Market Open | 1.23 |
| Regular Market Previous Close | 1.23 |
| Regular Market Price | 1.32 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 105,935 |
| Return On Assets | -0.31253 |
| Return On Equity | -1.19488 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 25,637,225 |
| Shares Percent Shares Out | 0.010299999 |
| Shares Short | 265,280 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 246,701 |
| Short Name | ABVC Biopharma, Inc. |
| Short Percent Of Float | 0.0127 |
| Short Ratio | 4.43 |
| Source Interval | 15 |
| State | CA |
| Symbol | ABVC |
| Total Cash | 745,834 |
| Total Cash Per Share | 0.03 |
| Total Debt | 3,473,126 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.41819 |
| Two Hundred Day Average Change | -1.09819 |
| Two Hundred Day Average Change Percent | -0.45413718 |
| Type Disp | Equity |
| Volume | 105,935 |
| Website | https://www.abvcpharma.com |
| Zip | 94,538 |